Document:

exv10w37

Exhibit 10.37

Non-Employee Director Compensation Summary

Alseres Pharmaceuticals, Inc.’s (the “Company’s”) non-employee directors currently consist of:
William L.S. Guinness; Robert S. Langer, Jr.; Michael J. Mullen; John T. Preston; Gary E. Frashier;
and Henry Brem.

For the
year ended December 31, 2008, the Company’s non-employee
director compensation was earned as
follows, however, the Company has only paid non-employee director
compensation through June 30, 2008:

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Per Board and	 	 
	 	 	 	 	 	 	Committee	 	Annual Fee Per
	 	 	2008 Annual	 	 	 	 
	 	 	Retainer	 	Meeting Fees (1)	 	Committee Chaired
	William L.S. Guinness
	 	$	25,000	 	 	$	2,500	 	 	 	—	 
	Robert S. Langer, Jr.
	 	$	25,000	 	 	$	2,500	 	 	$	10,000	 
	Michael J. Mullen
	 	$	25,000	 	 	$	2,500	 	 	$	20,000	 
	John T. Preston
	 	$	25,000	 	 	$	2,500	 	 	$	20,000	 
	Gary E. Frashier 
	 	$	25,000	 	 	$	2,500	 	 	$	10,000	 
	Henry Brem 
	 	$	25,000	 	 	$	2,500	 	 	 	—	 

 

			
	(1)	 	Board and committee fees are paid on a per meeting basis at $2,500 per meeting.

All non-employee directors are reimbursed for ordinary and reasonable expenses of attending any
board or committee meetings.

Each new non-employee director is automatically granted an option to purchase 25,000 shares of the
Company’s common stock (“New Director Options”) upon initial election or appointment (the
“Automatic Grant Date”). The exercise price of any New Director Options granted shall equal the
fair market value of shares of the Company’s common stock subject thereto on the Automatic Grant
Date. New Director Options immediately vest as to 1/3 of the shares subject to such New Director
Options with the remaining 2/3 of the shares subject to such New Director Option vesting in equal
monthly installments over two years (“New Director Option Vesting”).

Each non-employee director is automatically granted an option to purchase 25,000 shares of the
Company’s common stock each year (“Annual Director Options”). The Annual Director Options are
granted in the fourth quarter of each calendar year (the “Annual Grant Date”). The exercise price
of any Annual Director Options granted shall equal the fair market value of shares of the Company’s
common stock subject thereto on the Annual Grant Date. Annual Director Options vest in equal
monthly installments over two years (“Annual Director Option Vesting”). Newly elected non-employee
directors are eligible to receive the Annual Director Options in the fourth quarter of the second
calendar year of service.exv10w38

Exhibit 10.38

Executive Officer Compensation Summary

Alseres Pharmaceuticals, Inc.’s (the “Company’s”) executive officers consist of: (i) Peter G.
Savas, Chairman and Chief Executive Officer; (ii) Mark J. Pykett, President and Chief Operating
Officer; and (iii) Kenneth L. Rice, Jr., Executive Vice President, Finance and Administration,
Chief Financial Officer and Secretary.

2008 Incentive Compensation and 2009 Annual Base Salary: In January 2009, the compensation
committee of the board of directors approved the following 2008 incentive compensation amounts for
the executive officers and the following new base salaries for 2009, effective January 1, 2009:

	 	 	 	 	 	 	 	 	 
	 	 	2008 Incentive	 	2009 Annual
	 	 	Compensation	 	Base Salary
	Mr. Savas
	 	$	—	 	 	$	401,625	 
	Mr. Pykett
	 	$	—	 	 	$	303,450	 
	Mr. Rice
	 	$	—	 	 	$	267,750exv10w44

EXHIBIT 10.44

ALSERES PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED

1990 NON-EMPLOYEE DIRECTORS’ NON-QUALIFIED STOCK OPTION PLAN

1. Objectives.

     The objectives of the Alseres Pharmaceuticals, Inc. Second Amended and Restated 1990
Non-Employee Directors’ Non-Qualified Stock Option Plan (as amended from time to time, the “Plan”)
are to assist Alseres Pharmaceuticals, Inc. (the “Company”) in attracting and retaining experienced
and knowledgeable independent Directors, to further promote the identification of such Directors’
interests with those of the Company’s stockholders, and to attract and retain experienced and
knowledgeable employees, independent contractors and consultants. The Alseres Pharmaceuticals, Inc.
Second Amended and Restated 1990 Non-Employee Directors’ Non-Qualified Stock Option Plan is hereby
amended and restated.

2. Maximum Number of Shares to be Optioned and Adjustments in Optioned Shares.

     The maximum number of shares of common stock, par value $.01 per share (the “Common Stock”),
of the Company which may be issued hereunder is 1,400,000 (the “Shares”).

     In the event of any dividend or other distribution (whether in the form of cash, Common Stock,
or other property), recapitalization, stock split, reverse split, reorganization, merger,
consolidation, spin-off, combination, repurchase, or share exchange, or other similar corporate
transaction or event, then the Board of Directors of the Company (the “Board”) shall make equitable
adjustments in the manner determined by the Board to any or all of (i) the number and kind of
shares of Common Stock which may thereafter be issued in connection with options, (ii) the number
and kind of shares of Common Stock issuable in respect of outstanding options, and (iii) the
exercise price relating to any option.

3. Administration and Interpretation.

     The Plan shall be administered by a committee (the “Committee”) appointed by the Board.
Subject to the express provisions of the Plan, the Committee may make such rules and establish such
procedures as it deems appropriate for the administration of the Plan. In the event of any
disagreement as to the interpretation of the Plan or any rule or procedure thereunder, the decision
of the Committee shall be final and binding upon all persons in interest.

4. Annual Grant of Options.

     Each member (a “Director”) of the Board who is not an employee of the Company and who has not
been an employee of the Company for a period of at least one year prior to the date of grant of an
option under the Plan (a “Non-Employee Director”) shall automatically be granted an option on the
thirteenth trading day after the date of the annual meeting of stockholders of the Company
(“Retainer Grant Date”) to purchase such number of Shares equal to the lesser of (a) 2,500 Shares
and (b) the quotient of the annual retainer for service as a Non-Employee Director of the Company
and 80% of the average of the fair market value of a Share of Common Stock on the ten trading days
following the third trading day after the date of such annual meeting of stockholders of the
Company (such average a “Ten Day Average-Value”). If the number of Shares calculated pursuant to
clause (b) of the immediately preceding sentence exceeds 2,500, each Non-Employee Director entitled
to receive Shares under this paragraph of Section 4 will automatically receive on the Retainer
Grant Date a cash payment equal to the annual retainer minus the product of 2,500 and 80% of the
Ten Day Average Value. The “fair market value” of Shares shall be determined to be the closing
price per Share on the principal national securities exchange on which the Share is listed or
admitted to trading, or, if not listed or traded on any such exchange, on the Nasdaq National
Market, or if not listed or traded on any such exchange or system, the average of the bid and asked
price per Share on Nasdaq or, if such quotations are not available, the fair market value of a
Share as determined in good faith by the Committee, which determination shall be conclusive.

     Each person who is newly elected or appointed a Non-Employee Director after the Company’s
annual meeting of stockholders held in 1995, but not by election at a subsequent Company annual
meeting of stockholders, shall automatically, on the thirteenth trading day after the date of such
election or appointment (the “Mid-Year Grant Date”), be granted options to purchase such number of
Shares equal to the lesser of (a) 2,500 Shares and (b) the quotient of (i) the product of (x) the
annual retainer for service as a Director of the Company and (y) a fraction (the “Fraction”), the
numerator of which is the number of whole months from the date of such election or appointment as a
Non-Employee Director until the date of the next annual meeting of stockholders and the denominator
of which is 12 (such product hereinafter known as the “Mid-Year Retainer Amount”) and (ii) 80% of
the average of the fair market value of a Share on the ten trading days following the third trading day after the date of such
election or appointment (such average a “Mid-Year Ten Day Average Value”). If the number of Shares
calculated pursuant to clause (b) of the immediately preceding sentence exceeds 2,500, each
Non-Employee Director entitled to receive Shares under this paragraph of Section 4 will
automatically receive on

 

 

the Mid-Year Grant Date a cash payment equal to the Mid Year Retainer
Amount minus the product of 2,500 and 80% of the Mid Year Ten Day Average Value.

5. Grants to New Non-Employee Directors.

     Each Non-Employee Director who, after the Company’s annual meeting of stockholders held in
1994, is elected or appointed to the Board for the first time, and who was not immediately prior to
such date serving on the Board of Directors of Alseres Pharmaceuticals, Inc., will, at the time
such director is elected or appointed and duly qualified, be granted automatically (the “Automatic
Grant Date”) an option to purchase 7,500 Shares.

6. Grants to Employees, Consultants, and Independent Contractors.

     The Board may, in its discretion grant stock options under the Director Plan to any employee,
independent contractor or consultant of the Company (each, an “Employee”) or to any Non-Employee
Director, and such options will have the terms and conditions set by the Board at the time the
option is granted.

7. Option Terms.

     Subject to the limitations prescribed in Sections 4 and 5 above, the options granted under the
Plan shall be on the terms stated in subsections 7(a) through (g) below.

     (a) The option exercise price per-share for options granted pursuant to Section 4 of this
Plan shall be 20% of the Ten Day Average Value or Mid-Year Ten Day Average Value per Share, as
appropriate. The option exercise price per share for options granted pursuant to Section 5 of
this Plan shall be 100% of the fair market value of a share of Common Stock on the Automatic
Grant Date.

     (b) Subject to the provisions herein regarding expiration or termination of options, an
option granted pursuant to Section 4 of the Plan shall become exercisable as to 75% of the
Shares subject thereto six months after the Retainer Grant Date or Mid-Year Grant Date of the
option, as appropriate, and shall become exercisable as to 100% of the Shares subject thereto
on the later of six months after the Retainer Grant Date or Mid-Year Grant Date, as
appropriate, and December 31 of the year in which the option is granted. Subject to the
provisions herein regarding expiration or termination of options, an option granted pursuant to
Section 5 of the Plan shall be exercisable as to 20% of the Shares subject thereto on the
Automatic Grant Date of the option, and shall become exercisable as to an additional 20% of the
Shares subject thereto each of the first, second, third and fourth anniversaries of such
Automatic Grant Date. No partial exercise of the option may be for less than 10 full Shares,
unless the number of shares so purchased constitutes the total number of shares then
purchasable under such option. In no event shall the Company be required to issue fractional
Shares.

     (c) Notwithstanding any other provisions of the Plan to the contrary, no option shall be
granted later than ten years after the date the Plan is adopted by the Board.

     (d) The option price shall be payable in cash, services rendered, personal property
(including Shares having a fair market value equal to the option price), real property, leases
of real property or any combination thereof.

     (e) The option shall not be transferable otherwise than by will or the laws of descent and
distribution and shall be exercisable, during the optionee’s lifetime, only by such optionee or
the optionees Representative (as hereinafter defined).

     (f) The option shall expire ten years after the date of grant, unless an earlier date is
fixed by operation of Section 7 hereof.

     (g) Change in Control

     Notwithstanding any other provision of the Plan to the contrary, if, while any options remain
outstanding under the Plan, a “Change in Control” of the Company (as defined in this Section 7(g))
shall occur, all options granted under the Plan that are outstanding at the time of such Change in Control shall become immediately exercisable in
full, without regard to the years that have elapsed from the date of grant.

     For purposes of this Section 7(g), a Change in Control of the Company shall occur upon the
happening of the earliest to occur of the following:

     (i) any “person,” as such term is used in Sections 13(d) and 14(d) of the Exchange Act
(other than (1) the Company, (2) any trustee or other fiduciary holding securities under an
employee benefit plan of Company, or (3) any corporation owned, directly or indirectly, by the
stockholders of the Company in substantially the same proportions as their ownership of Stock
(each an “excluded person”), is or becomes the “beneficial owner” (as defined in Rule 13d-3
under the Exchange Act), directly

 

 

or indirectly, of securities of the Company (not including in
the securities beneficially owned by such person any securities acquired directly from the
Company or its affiliates) representing 30% or more of the combined voting power of the
Company’s then outstanding voting securities;

     (ii) during any period of not more than two consecutive years, individuals who at the
beginning of such period constitute the Board, and any new director (other than a director
designated by a person who has entered into an agreement with the Company to effect a
transaction described in clause (i), (iii), or (iv) of this paragraph (g)) whose election by
the Board or nomination for election by the Company’s stockholders was approved by a vote of at
least two-thirds (2/3) of the directors then still in office who either were directors at the
beginning of the period or whose election or nomination for election was previously so approved
(other than approval given in connection with an actual or threatened proxy or election
contest), cease for any reason to constitute at least a majority of the Board;

     (iii) the stockholders of the Company approve a merger or consolidation of the Company
with any other corporation, other than (A) a merger or consolidation which would result in the
voting securities of the Company outstanding immediately prior thereto continuing to represent
(either by remaining outstanding or by being converted into voting securities of the surviving
or parent entity) 50% or more of the combined voting power of the voting securities of the
Company or such surviving or parent entity outstanding immediately after such merger or
consolidation, (B) a merger or consolidation effected to implement a recapitalization of the
Company (or similar transaction) in which no “person” (as hereinabove defined) acquired 30% or
more of the combined voting power of the Company’s then outstanding securities or (C) the
transaction contemplated by the Merger Agreement (as defined below); or

     (iv) the stockholders of the Company approve a plan of complete liquidation of the Company
or an agreement for the sale or disposition by the Company of all or substantially all of the
Company’s assets (or any transaction having a similar effect).

8. Exercise Rights upon Ceasing to be a Director, Employee, Independent Contractor or Consultant.

     (a) In the event that a Director, employee, independent contractor or consultant ceases to
serve as a Director, employee, independent contractor or consultant of the Company and its
subsidiaries due to death or Disability (as hereinafter defined), such optionee’s options may be
exercised at any time within 12 months following such optionee’s death or Disability (subject to
the limitations prescribed in Sections 4 or 5, as appropriate, and subsection 7(f) above) by the
optionee, the optionee’s legal representative or the person or persons to whom the optionee’s
rights under the options shall pass by will or by the laws of descent or distribution (each a
“Representative”), but only to the extent that the optionee’s options were exercisable on the date
of such optionee’s death or Disability.

     (b) If an optionee ceases to be a Director, employee, independent contractor or consultant of
the Company as the result of a termination without cause (other than due to death or Disability),
his options will continue to vest for a period of one year pursuant to the vesting schedule
established at the time the option was granted, and (A) any options held by such optionee that were
exercisable on the date of such termination may be exercised by the optionee until the later of:
(i) one year following the date of such termination, or (ii) one year from the date any option
vests in the twelve month period following such termination, and (B) any options held by such
optionee that vested during the 12-month period following the date of termination may be exercised
by the optionee for a period of one year following the date of such vesting (subject to the
limitations prescribed in Sections 4 or 5, as appropriate, and subsection 7(f) above).

     (c) If an optionee ceases to be an employee, independent contractor, consultant or director of
the Company as the result of a voluntary resignation (other than due to death or disability), his
options will continue to vest for a period of one year pursuant to the vesting schedule established
at the time the option was granted, provided that the optionee has been an employee, independent
contractor, consultant or director of the Company for at least three years and has signed a
non-compete agreement with the Company (such agreement to include biotechnology companies, academic and/or research organizations
encompassing biotechnology, and venture capital companies in the biotechnology sector), and (A) any
options held by such optionee that were exercisable on the date of such resignation may be
exercised by the optionee until the later of: (i) one year following the date of such resignation,
or (ii) one year from the date any option vests in the twelve month period following such
resignation, and (B) any options held by such optionee that vested during the 12-month period
following the date of resignation may be exercised by the optionee for a period of one year
following the date of such vesting (subject to the limitations prescribed in Sections 4 or 5, as
appropriate, and subsection 7(f) above).

provided, that, if the optionee dies within such one-year period following termination of
employment or other relationship, the option (to the extent exercisable at the time of death) shall
be exercisable by the optionee’s Beneficiary for a period of one (1) year following the optionee’s
death (but in no event after the expiration date of the option), and shall thereafter terminate.

     The provisions of this paragraph 8 shall not apply to options held by any person who was a
Non-Employee Director of the Company prior to the Effective Date of the Merger (as those terms are
defined in the Agreement of Merger by and between Greenwich Pharmaceuticals Incorporated and
Alseres Pharmaceuticals, Inc., dated August 8, 1994 (the “Merger Agreement”) and who resigns as

 

 

such director of the Company immediately after such Effective Date. Any options issued to the
persons identified in the immediately preceding sentence and that remain outstanding as of the
Effective Date will remain outstanding for the remainder of their respective terms not to exceed
ten years from the date of grant. The term “Disability” shall mean the inability, due to illness or
injury, to engage in any gainful occupation for which the individual is suited by education,
training or experience, which condition continues for at least six months.

9. Exercise and Additional Requirements.

     Any optionee or Representative exercising an option may exercise the option (to the extent
exercisable as of such date) by delivery to the Company of (a) written notice of exercise of the
option as to a specified number of Shares; and (b) payment of the option exercise price for such
Shares.

     Upon the exercise of an option granted hereunder the Board may require the optionee or
Representative, as the case may be, exercising the option to deliver the following:

     (a) A written statement that the optionee or Representative, as the case may be, is
purchasing the Shares for investment and not with a view toward their distribution or sale and
will not sell or transfer any Shares received upon the exercise of the option except in
accordance with the Securities Act of 1933, as amended, and applicable state securities laws;

     (b) Evidence reasonably satisfactory to the Company that, at the time of exercise, the
optionee or Representative, as the case may be, meets such other requirements as the Board of
Directors may determine;

     (c) Evidence reasonably satisfactory to the Company that, at the time of exercise, the
exercise of the option by the optionee or Representative, as the case may be, and the delivery
of Shares by the Company comply with all applicable federal and state securities laws; and

     (d) Evidence reasonably satisfactory to the Company that, at the time of exercise of the
option by the optionee, such optionee has complied with the requirements of all applicable
federal, state and local income tax withholding laws.

10. Common Stock Subject to Option.

     The Shares issuable upon exercise of options granted hereunder may be unissued shares of
treasshares, including shares bought on the open market. The Company at all times during the term
of the Plan shall reserve for issuance the number of Shares issuable upon exercise of options
granted hereunder.

11. Compliance with Governmental and Other Regulations.

     The Company will not be obligated to issue and sell the Shares issued pursuant to options
granted hereunder if, in the opinion of its counsel, such issuance and sale would violate any
applicable federal or state securities laws. The Company will seek to obtain from each regulatory
commission or agency having jurisdiction such authority as may be required to issue and sell Shares
issuable upon exercise of any option granted hereunder. Inability of the Company to obtain from any
such regulatory commission or agency authority which counsel to the Company deems necessary for the
lawful issuance and sale of Shares upon exercise of an option granted hereunder shall relieve the Company from any liability for failure to issue and sell
such Shares until the time when such authority is obtained or is obtainable.

12. Nonassignment of Options.

     Except as otherwise provided in subsection 6(e) hereof, any option granted hereunder and the
rights and privileges conferred hereby shall not be transferred, assigned, pledged or hypothecated
in any way (whether by operation of law or otherwise) and shall not be subject to execution,
attachment or similar process. Upon any attempt to transfer, assign, pledge, hypothecate or
otherwise dispose of such option, right or privilege contrary to the provisions hereof, or upon the
levy of any attachment or similar process upon the rights and privileges conferred hereby, such
option and the rights and privilege conferred hereby shall immediately terminate.

13. Rights of Optionee in Stock.

     Neither any optionee nor the Representative, heirs, legatees or distributees of any optionee,
shall be deemed to be the holder of, or to have any of the rights of a holder with respect to any
Shares issuable upon exercise of an option granted hereunder unless and until such Shares are
issued to such optionee or Representative, as the case may be, and a certificate has been issued
therefore.

14. Delivery of Shares Issued Pursuant to Option.

 

 

     Subject to the other terms and conditions of the Plan, upon the exercise of an option granted
hereunder, the Company shall sell and deliver to the optionee or Representative, as the case may
be, the Shares with respect to which the option has been exercised.

15. Withholding of Applicable Taxes.

     The Company shall have the right to reduce the number of Shares otherwise required to be
issued upon exercise of an option granted hereunder by an amount equal to all federal, state, city
or other taxes as shall be required to be withheld by the Company pursuant to any statute or other
governmental regulation or ruling divided by the fair market value per Share on the date of such
exercise (or such other date as may be required under applicable law). In connection with such
withholding, the Company may make any such arrangements as are consistent with the Plan as it may
deem appropriate.

16. Plan and Options Not to Affect Directorship.

     Neither the Plan nor any option granted hereunder shall confer upon any individual any right
to continue as a Director of the Company.

17. Amendment of Plan.

     The Board may make any amendments to the Plan which it deems necessary or advisable, provided
that the Board may seek stockholder approval of an amendment if it is determined to be required by
or advisable under regulations of the Securities and Exchange Commission or the Internal Revenue
Service, the rules of any stock exchange or system on which the Company’s capital stock is listed
or other applicable law or regulation.

18. Notices.

     Any notice required or permitted hereunder shall be in writing and shall be sufficiently given
only (i) if personally delivered, (ii) if sent by telex or facsimile, provided that “answer back”
confirmation is received by sender or (iii) upon receipt, if sent by registered or certified mail,
postage prepaid, addressed to the Company, c/o Alseres Pharmaceuticals, Inc., 239 South Street,
Hopkinton, Massachusetts 01748 and to the optionee at the address on file with the Company at the
time of grant hereunder, or to such other address as either party may hereafter designate in
writing by notice similarly given by one party to the other.

19. Successors.

     The Plan shall be binding upon and inure to the benefit of any successor or successors of the
Company.

20. Severability.

     If any part of the Plan shall be determined to be invalid or void in any respect, such
determination shall not affect, impair, invalidate or nullify the remaining provisions of the Plan
which shall continue in full force and effect.

21. Governing Law.

     The Plan and all determinations made and actions taken pursuant hereto shall be governed by
the laws of the State of Delaware without giving effect to the conflict of laws principles thereof.

22. Termination of the Plan.

     The Board may terminate the Plan at any time; otherwise the Plan shall terminate on April 23,
2005. Termination of the Plan shall not deprive optionees of their rights under previously granted
options.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]